Riskpilot← Back to searchSign inGet full accessVEPIDAN ApS
APSActiveCVR 17077848Østerbrogade 23Wholesale of pharmaceutical and medical goods · NACE 4646Est. 199339 employees
Revenue 2025
DKK 5,8M
0% vs 2024
EBITDA margin
12.4%
+371% vs 2024
Equity ratio
82.1%
Financial strength
Net profit 2025
DKK 2,9M
+338% vs 2024
| Revenue | DKK 5,8M | +0% |
| EBITDA | DKK 725K | +371% |
| Net profit | DKK 2,9M | +338% |
| Total assets | DKK 133,1M | -3% |
| Equity | DKK 109,3M | +3% |
| Employees | 39 | — |
Legal name
VEPIDAN ApS
CVR number
17077848
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. juni 1993
Share capital
DKK 200.000
Employees
39 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er fremstilling og forhandling af lægemidler og dermed beslægtede varer.
Address
Østerbrogade 23
Phone
+4598673388
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.302 | 15.494 | 33.850 | 12.702 | 9.923 | 9.247 | 7.911 | 9.589 | 9.442 | 7.849 | 4.469 | 6.146 | 5.818 | 5.847 |
| Staff expenses | -5.341 | -4.940 | -5.249 | -5.491 | -5.523 | -6.373 | -7.287 | -6.515 | -6.865 | -8.032 | -6.653 | -6.078 | -5.664 | -5.122 |
| EBITDA | 7.961 | 10.554 | 10.568 | 7.211 | 4.400 | 2.874 | 625 | 3.074 | 2.577 | -183 | -2.184 | 68 | 154 | 725 |
| Depreciation & amort. | -152 | -12 | -47 | -246 | -352 | -357 | -425 | -278 | -83 | -238 | -228 | -276 | -276 | -399 |
| EBIT | 7.809 | 10.542 | 10.520 | 6.965 | 4.049 | 2.516 | 200 | 2.797 | 2.494 | -421 | -2.412 | -208 | -122 | 326 |
| Net financials | -283 | 760 | 1.790 | 3.779 | 1.545 | 4.468 | -3.231 | 3.358 | 11.041 | 48.611 | -3.303 | -13.666 | -1.138 | 2.531 |
| Profit before tax | 7.526 | 11.302 | 12.310 | 10.743 | 5.593 | 6.985 | -3.031 | 6.155 | 13.534 | 48.190 | -5.715 | -13.874 | -1.259 | 2.857 |
| Tax | 2.053 | 2.848 | 3.024 | 2.539 | 1.236 | 1.391 | -647 | 1.371 | 2.979 | 10.613 | 71 | -57 | -18 | -92 |
| Net profit | 5.472 | 8.455 | 9.286 | 8.204 | 4.357 | 5.594 | -2.384 | 4.784 | 10.556 | 37.577 | -5.786 | -13.817 | -1.242 | 2.950 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 41.176 | 41.625 | 48.082 | 55.294 | 58.498 | 61.974 | 58.268 | 64.410 | 76.740 | 122.815 | 152.547 | 158.416 | 136.863 | 133.077 |
| Equity | 16.473 | 24.783 | 33.924 | 41.981 | 46.188 | 51.630 | 49.092 | 53.717 | 64.110 | 101.522 | 95.736 | 107.551 | 106.310 | 109.260 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 24.703 | 16.842 | 14.158 | 13.284 | 12.291 | 10.325 | 9.177 | 10.694 | 12.616 | 21.287 | 56.810 | 50.865 | 30.553 | 23.818 |
| Total debt | 24.703 | 16.842 | 14.158 | 13.284 | 12.291 | 10.325 | 9.177 | 10.694 | 12.616 | 21.287 | 56.810 | 50.865 | 30.553 | 23.818 |
EBITDA margin
12.4%
This company
15.8%
Market median
-22% vs market
20122025
Equity ratio
82.1%
This company
38.2%
Market median
+115% vs market
20122025
Return on equity
2.7%
This company
18.4%
Market median
-85% vs market
20122025
Net profit margin
50.5%
This company
8.1%
Market median
+523% vs market
20122025
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20122025
Debt / equity
0.22×
This company
0.62×
Market median
+65% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HL Audit | Audit | 1993 | — | — |
ET | Audit | 1993 | — | — |
HG Management | Management | 1993 | — | — |
PE Management | Management | 1993 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2014 | |
| Individual | 33.3% | 33.3% | 2014 | |
| Individual | 33.3% | 33.3% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VEPIDAN ApS (this company)
Nectar HV Holding ApSBoard members of VEPIDAN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henning Lind | Audit | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Hanne Graversen | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |